American Association for Cancer Research (AACR) Annual Meeting 2023
Orlando, Florida, US 14 April 2023 - 19 April 2023
Add-on mRNA cancer vaccine delivers promise for melanoma
20 Jun 2023
bởiAudrey Abella
Adding mRNA-4157, an investigational personalized neoantigen cancer vaccine, to the immune checkpoint inhibitor (ICI) pembrolizumab significantly improved recurrence-free survival (RFS) in individuals with resected high-risk melanoma, findings from the phase IIb KEYNOTE 942 study suggest.
Add-on mRNA cancer vaccine delivers promise for melanoma
20 Jun 2023
Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC
12 Jun 2023
bởiAudrey Abella
In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.